MESA LABORATORIES INC /CO/
No SEC Form 4 filings for $MLAB in the last 30 days.
See all $MLAB insider activity →Mesa Laboratories (MLAB) plans to cut 40 jobs, or 6% of its workforce, primarily in its Clinical Genomics division, to save $9.3M annually. The company will reinvest $4.3M into growth initiatives, including business development and commercial resources in Asia. MLAB pre-market price: $128.07.
MESA LABORATORIES INC /CO/ (MLAB) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Mesa Laboratories Announces Restructuring and Savings Plan to Reduce Annualized Costs by Approximately $9.3 Million and Reinvest Approximately $4.3 Million in Profitable Growth The Restructuring Program focuses Clinical Genomics on profitability and adds resources in
Mesa Laboratories (MLAB) declared a quarterly dividend of $0.16 per share, payable Dec 15, 2026 to shareholders of record on Nov 30, 2026. The company's dividend policy remains unchanged.
Over the past 7 days, AlphAI's AI scored 4 news stories mentioning MLAB (MESA LABORATORIES INC /CO/). Coverage has skewed bullish: 1 bullish, 3 neutral, and 0 bearish.
Recent MLAB coverage spans corporate actions, earnings and insider activity.
Cost‑saving measures may weigh on the stock short‑term but reinvestment could support growth.
Cost takeout and Clinical Genomics repositioning should improve margins over time, but near-term results may be pressured by restructuring charges and lower Clinical Genomics revenue.
The dividend announcement may provide modest support to the stock price as investors price in the new yield.
Board composition changes may affect governance and strategic direction.
Execution-driven weakness in SDC delivery timing contrasts with margin expansion and debt reduction progress, shaping near-term sentiment and risk.
AlphAI scores every news story that mentions MLAB with an AI model for sentiment and relevance, and aggregates insider trades from MESA LABORATORIES INC /CO/'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Mesa Laboratories (MLAB) plans to cut 40 jobs, or 6% of its workforce, primarily in its Clinical Genomics division, to save $9.3M annually. The company will reinvest $4.3M into growth initiatives, including business development and commercial resources in Asia. MLAB pre-market price: $128.07.
1 min readMESA LABORATORIES INC /CO/ (MLAB) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Mesa Laboratories Announces Restructuring and Savings Plan to Reduce Annualized Costs by Approximately $9.3 Million and Reinvest Approximately $4.3 Million in Profitable Growth The Restructuring Program focuses Clinical Genomics on profitability and adds resources in
6 min readMesa Laboratories (MLAB) declared a quarterly dividend of $0.16 per share, payable Dec 15, 2026 to shareholders of record on Nov 30, 2026. The company's dividend policy remains unchanged.
1 min readMESA LABORATORIES INC /CO/ (MLAB) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 8, 2026 MESA LABORATORIES, INC. (Exact name of regist
1 min readMesa Laboratories (MLAB) reported Q1 FY2027 revenues of $60.1 million, up 1% year over year, with core organic growth of 0.4%. Adjusted operating income was $15.4 million, up 19.5%, and gross margin rose to 64.9%. Net leverage fell to 1.85x after $8.7 million debt repayment. SDC revenue was $24.5 million, down 3.6% organically.
6 min readSullivan John James sold 7,093 shares of MESA LABORATORIES INC /CO/ (MLAB) at $112.80 ($0.80M total) on 2026-08-13.
1 min readKadia Siddhartha (President and CEO) purchased 7,093 indirectly-held shares of MESA LABORATORIES INC /CO/ (MLAB) at $112.80 ($0.80M total) on 2026-08-13.
1 min readTripeny R Tony purchased 900 shares of MESA LABORATORIES INC /CO/ (MLAB) at $113.69 ($0.10M total) on 2026-08-13.
1 min readMesa Laboratories (MLAB) Q1 2027 earnings call highlighted margin expansion and progress on debt reduction. Management said SDC organic revenue fell 3.6% YoY due to delivery reliability issues, with past-due backlog up about $1M. BPD grew 5% but turnaround is ongoing. GAAP net income fell 40.3% on currency swings. Net leverage was 1.85x, effective rate 5.6%, targeting 1.5x to 1.75x.
6 min readMESA LABORATORIES INC /CO/ (MLAB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Mesa Labs Announces First Quarter Results Lakewood, Colorado , August 10, 2026 – Mesa Laboratories, Inc. (NASDAQ:MLAB) (“Mesa” or the “Company”), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announc
6 min read
